Chesapeake Capital Corp IL Makes New $422,000 Investment in Insulet Co. (NASDAQ:PODD)

Chesapeake Capital Corp IL purchased a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 1,617 shares of the medical instruments supplier's stock, valued at approximately $422,000.

Other hedge funds have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet during the 4th quarter worth approximately $36,000. SRS Capital Advisors Inc. grew its position in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after buying an additional 56 shares during the period. TD Private Client Wealth LLC grew its position in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after buying an additional 56 shares during the period. Friedenthal Financial acquired a new stake in shares of Insulet during the 4th quarter worth approximately $57,000. Finally, Assetmark Inc. grew its position in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after buying an additional 246 shares during the period.

Insulet Price Performance

PODD traded up $1.46 during midday trading on Friday, hitting $266.85. The stock had a trading volume of 737,253 shares, compared to its average volume of 686,965. The company has a market cap of $18.74 billion, a P/E ratio of 46.01, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The business has a fifty day moving average of $272.11 and a 200 day moving average of $256.26. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46.

Remove Ads

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, equities analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PODD shares. Raymond James reissued an "outperform" rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. StockNews.com downgraded shares of Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Canaccord Genuity Group lifted their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Piper Sandler lifted their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Finally, Wells Fargo & Company lifted their price objective on shares of Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, Insulet currently has a consensus rating of "Moderate Buy" and an average price target of $292.06.

Insider Buying and Selling at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.47% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.